Twist Bioscience/$TWST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Twist Bioscience
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Ticker
$TWST
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
923
ISIN
US90184D1000
Website
Twist Bioscience Metrics
BasicAdvanced
$2.2B
-
-$3.25
2.54
-
Price and volume
Market cap
$2.2B
Beta
2.54
52-week high
$60.90
52-week low
$27.12
Average daily volume
1.2M
Financial strength
Current ratio
4.514
Quick ratio
4.096
Long term debt to equity
14.787
Total debt to equity
18.245
Interest coverage (TTM)
-801.23%
Profitability
EBITDA (TTM)
-131.099
Gross margin (TTM)
46.70%
Net profit margin (TTM)
-54.98%
Operating margin (TTM)
-44.94%
Effective tax rate (TTM)
-0.19%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-15.04%
Return on equity (TTM)
-38.22%
Valuation
Price to revenue (TTM)
6.258
Price to book
5.02
Price to tangible book (TTM)
6.5
Price to free cash flow (TTM)
-33.222
Free cash flow yield (TTM)
-3.01%
Free cash flow per share (TTM)
-111.19%
Growth
Revenue change (TTM)
25.30%
Earnings per share change (TTM)
-3.16%
3-year revenue growth (CAGR)
28.70%
3-year earnings per share growth (CAGR)
-4.44%
What the Analysts think about Twist Bioscience
Analyst ratings (Buy, Hold, Sell) for Twist Bioscience stock.
Bulls say / Bears say
Twist Bioscience reported a 23.2% year-over-year revenue increase to $92.79 million in Q2 FY2025, surpassing analyst expectations of $91.99 million, indicating strong demand for its products. (TradingView News)
Analysts have raised the stock's price target, with TD Cowen increasing it to $65.00 from $55.00, citing optimism about the company's growth potential and path to profitability. (Investing.com)
Twist Bioscience's strategic positioning in the synthetic DNA market is considered undervalued, especially amid macroeconomic tensions between the U.S. and China, potentially leading to market share gains. (Investing.com)
The company reported a quarterly adjusted loss of $0.66 per share in Q2 FY2025, missing analyst expectations of a $0.58 loss, raising concerns about its path to profitability. (TradingView News)
Twist Bioscience's biopharma segment underperformed, leading to a significant impairment charge and casting doubt on the company's diversification efforts. (Seeking Alpha)
Executives and directors are facing a shareholder derivative lawsuit alleging misrepresentation of the company's growth potential and technology, which could impact investor confidence. (Bloomberg Law)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Twist Bioscience Financial Performance
Revenues and expenses
Twist Bioscience Earnings Performance
Company profitability
Twist Bioscience News
AllArticlesVideos
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire·1 month ago
Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results
Business Wire·2 months ago
Twist Bioscience Spins Out DNA Data Storage as Independent Company
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Twist Bioscience stock?
Twist Bioscience (TWST) has a market cap of $2.2B as of June 27, 2025.
What is the P/E ratio for Twist Bioscience stock?
The price to earnings (P/E) ratio for Twist Bioscience (TWST) stock is 0 as of June 27, 2025.
Does Twist Bioscience stock pay dividends?
No, Twist Bioscience (TWST) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Twist Bioscience dividend payment date?
Twist Bioscience (TWST) stock does not pay dividends to its shareholders.
What is the beta indicator for Twist Bioscience?
Twist Bioscience (TWST) has a beta rating of 2.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.